Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Hansa Biopharma Completes Enrollment in Anti-GBM

LUND, Sweden, Jan. 27, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the patient enrollment in an investigator-initiated phase 2 study to evaluate safety, tolerability and efficacy of imlifidase in 15 patients with severe Anti-GBM antibody disease has now been completed. A first data read out is expected in the third quarter of 2020.

"I am very pleased that we have now completed the enrollment of patients in the Anti-GBM antibody disease study. This marks an important milestone in Hansa Biopharma's efforts to develop potentially lifesaving and lifealtering therapies for patients with rare immunological diseases within a range of therapeutic areas, where there is a significant unmet medical need," says Søren Tulstrup, President and CEO, Hansa Biopharma. "Anti-GBM is the first IgG-mediated disease outside transplantation, where imlifidase is being investigated to potentially stop an immunologic attack."

Anti-GBM antibody disease, also known as Goodpasture's disease, is a severe kidney disease where the immune system mistakenly develops IgG-antibodies, resulting in an acute immune attack on the kidneys and in some patients also on the lungs. Severe Anti-GBM antibody disease may progress to renal failure or death. Most of the patients are experiencing significant loss of kidney function requiring chronic dialysis and kidney transplantation. Anti-GBM antibody disease affects roughly one in a million annually.

Hansa Biopharma was granted orphan drug designation for imlifidase for Anti-GBM antibody disease in both the EU and the US in 2018. 

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46-(0)-709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46-(0)-733-328 634
E-mail: rolf.gulliksen@hansabiopharma.com

This information was brought to you by Cision http://news.cision.com


The following files are available for download:


Hansa Biopharma completes enrollment in anti-GBM



SOURCE Hansa Biopharma AB

These press releases may also interest you

at 13:48
YourEncore, a strategic consultancy specializing in Quality, Regulatory, and Clinical challenges in the Life Sciences industry, today announced that the firm has expanded their Quality and Compliance portfolio to include a new Quality Management...

at 13:47
Today, Mars Wrigley, the world's largest candy maker known for treats like M&M'S®, SNICKERS®, TWIX® and SKITTLES®, launched its newest innovation ? TREAT TOWNtm ? a first-ever digital Halloween trick-or-treating experience. Created to save Halloween...

at 13:47
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Virtual lnvestor Conference focused on gold mining investment opportunities in the Province of Quebec. Individual investors,...

at 13:44
Sinclair Broadcast Group, Inc. ("Sinclair") is pleased to announce that the company and several employees have received Cynopsis' Media Awards. The Cynopsis Awards honor individual talent and companies who push the media industry forward,...

at 13:41
The S-Factor Co. (the "S-Factor" or the "Company"), a private technology firm providing the most comprehensive set of social impact data currently available on the market, has announced the launch of its final seed fundraising round via a private...

at 13:40
Packaging Technology Group, Inc (PTG), a leading provider of thermal packaging solutions for the biopharmaceutical and life sciences sector, responds to the global pandemic with the launch of its off-the-shelf line of pre-qualified shippers,...

News published on 27 january 2020 at 02:31 and distributed by: